Top Abstract Purchase Related
Home
>
Node
>
Subnode

Development of antibody drugs targeting against HER2 for cancer therapy

Tang, Q.; Ding, Q.; Lin, L.; Zhang, Z.-z.; Dai, Z.; Zhan, J.-b.

Yao Xue Xue Bao 47(10): 1297-1305

2012

ISSN/ISBN: 0513-4870
PMID: 23289141
Document Number: 657569
Human epidermal growth factor receptor 2 (HER2) belongs to the transmembrane glycoprotein receptor family. Overexpression of HER2 could directly lead to tumorigenesis and metastasis. This phenomenon could be observed in the breast cancer, ovarian cancer, gastric cancer, lung cancer and prostate cancer. Compared with the conventional chemotherapy, the targeted treatment of antibody is more specific and has lower side effects. This review describes the current status of monotherapy and combination therapies of anti-HER2 antibodies, trastuzumab and pertuzumab, with chemotherapeutic drugs. The development trends of new formats of anti-HER2 antibody drugs such as bispecific antibody, immunotoxin are also discussed.

Document emailed within 1 workday
Secure & encrypted payments

Yamaguchi, T.; Takahashi, T.; Kitamura, K.; Otsuji, E.; Kotani, T.; Kato, M.; Yata, Y.; Okamoto, K.; Nishi, H.; Ichikawa, D.; Yamamoto, K. 1996: Diagnosis and targeting therapy of colorectal cancer using antibody Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(5): 549-553
Kalland, T. 2005: Antibody-based cancer drugs: developing antibody therapeutic approaches to deliver individualized cancer drugs Idrugs: the Investigational Drugs Journal 8(5): 364-365
Tsuno, H.; Okaji, Y.; Tanaka, M.; Nagawa, H.; Takahashi, K. 2005: Development of a novel anti-cancer therapy based on targeting of tumor microvessel endothelial cells Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl 9): 527-533
Hayashi, S.; Hanamura, T. 2011: Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy Clinical Calcium 21(3): 389-396
Takashima, A.; Fukuda, H.; Shibata, T. 2010: Development for and clinical trials of molecular targeting drugs Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(5): 822-827
Bifulco, M.; Di Marzo, V. 2003: The endocannabinoid system as a target for the development of new drugs for cancer therapy Recenti Progressi in Medicina 94(5): 194-198
Lu, Z.; Song, Q.; Song, Q.; Jiang, S.; Yang, J.; Luo, F. 2010: Preparation of monoclonal antibody against lung cancer and identification of its targeting antigen Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 27(1): 147-151
Kato, K. 2011: Development of oral drugs in the standard therapy for metastatic colorectal cancer patients Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 3): 454-458
Hait, W.N. 1987: Targeting calmodulin for the development of novel cancer chemotherapeutic agents Anti-Cancer Drug Design 2(2): 139-149
Shiota, M.; Yokomizo, A.; Naito, S. 2014: The development of therapeutics targeting oxidative stress in prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2131-2135
Hortobagyi, G.N.; Khayat, D. 2000: Targeting progress: the development of growth factor receptor-directed therapy Seminars in Oncology 27(5 Suppl 9: 1-2
Uchino, J.; Une, Y.; Kamiya, T.; Kawata, A. 1994: Progress in targeting therapy for hepatic cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 765-771
Gardlik, R.; Celec, P.; Bernadic, M. 2011: Targeting angiogenesis for cancer (gene) therapy Bratislavske Lekarske Listy 112(8): 428-434
Naka, N. 2012: II. Possibility of molecular targeting therapy for musculoskeletal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(3): 373-377
Tahara, M. 2012: II. Molecular targeting therapy for head and neck cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(7): 1055-1060
Dwarakanath, B.S.; Verma, A.; Bhatt, A.N.; Parmar, V.S.; Raj, H.G. 2008: Targeting protein acetylation for improving cancer therapy Indian Journal of Medical Research 128(1): 13-21
Fujii, M. 2013: IV. Molecular targeting therapy for head and neck cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(7): 867-870
Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
Okita, R.; Yamaguchi, Y.; Ohara, M.; Hironaka, K.; Okawaki, M.; Nagamine, I.; Ikeda, T.; Emi, A.; Hihara, J.; Okada, M. 2009: Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer International Journal of Oncology 34(2): 563-572
Tanaka, T.; Kuroki, M.; Hamada, H.; Kato, K.; Kinugasa, T.; Shibaguchi, H.; Zhao, J.; Kuroki, M. 2007: Cancer-targeting gene therapy using tropism-modified adenovirus Anticancer Research 27(6a): 3679-3684